MediciNova’s MN-166 Is Safe, Shows Early Signs of Efficacy in Phase 2 Trial

MediciNova announced successful top-line results from a Phase 2 clinical trial of MN-166 (ibudilast) as an adjunct therapy to Rilutek (riluzole) in patients with amyotrophic lateral sclerosis (ALS). The treatment was safe and well-tolerated – meeting the trial’s primary endpoint – and was found to be more effective at…

Ludwig Cancer Research scientist Don Cleveland has received a $3 million Breakthrough Prize for increasing science’s understanding of how an inherited form of amyotrophic lateral sclerosis develops. His work focused on glia, cells that support the body’s production of a protein called myelin, which protects nerve cells. Deterioration of myelin…

https://vimeo.com/147387124 In 2015, the Cure for MND Foundation visited the RipCurl Pro Bells Beach in Australia and chatted with some of the world’s top surfers about the best waves, worst wipeouts and a somewhat surprising topic: motor neuron disease. MORE: Find out more about a group of ladies…

Scientists have long believed that ALS was confined to one area of the brain, but an Irish study shows it affects a number of regions. Researchers at Trinity College Dublin’s Academic Unit of Neurology used electroencephalography, or EEG, to record patients’ brain activity. They discovered that nerve cell communication was lower…

https://vimeo.com/165626427 There are currently around 30,000 people in the U.S. living with ALS and that number grows by approximately 15 each day. MORE: Learn about Nanci, a much-loved Hollywood publicist who was diagnosed with amyotrophic lateral sclerosis in 2014 This ALS Association of Texas video explains amyotrophic lateral…

Amyotrophic lateral sclerosis (ALS) patients with locked-in syndrome reported having a satisfactory quality of life and low levels of depression, in spite of their near-complete disability, in a small but recent study. The results of the questionaire-based study were presented by its lead author, Dorothée Lulé, at the 28th…

  Amyotrophic lateral sclerosis (ALS) is commonly referred to as Lou Gehrig’s disease. But who was Lou Gehrig? Henry Louis Gehrig was born in New York on June 19, 1903, at a time when very few people were aware of ALS, the progressive and neurodegenerative disease. Gehrig grew up to…

  Seize the Day! Lately that’s been my morning mental mantra. I visualize it as a chant and it’s the secret weapon I use every December to help me adjust to the onset of winter and face the end of the year. Even though I’m lucky to live…

BrainStorm Cell Therapeutics released new data on potential biomarkers from its Phase 2 trial investigating NurOwn, the company’s cell therapy for amyotrophic lateral sclerosis (ALS), at the International Symposium on ALS/MND meeting held in Boston last week. Both these findings and an ongoing Phase 3 trial, now recruiting patients in…

Pivotal Phase 3 clinical trial results presented at this year’s 28th International Symposium on ALS/MND reveal that Cytokinetics‘ investigational therapy tirasemtiv failed to provide a positive therapeutic impact on both muscle strength and slow vital capacity (SVC) in ALS patients. The results, which were presented by Jeremy Shefner, MD,…